Transgene Announces Opening of First Clinical Site for its Phase II Trial of TG4040 for the Treatment of Chronic Hepatitis C

13-Jul-2010 - Transgene S.A. announced the opening of the first clinical site for the phase II trial (named HCVac) of TG4040 (MVA-HCV) for the treatment of naïve genotype 1 hepatitis C infected patients in combination with standard of care (Pegylated-Interferon Alpha and Ribavarin). HCVac is a phase II ...

TcLand Expression signs a licensing agreement with Inserm Transfert

Strategic collaboration on the development of companion diagnostic tests for rheumatoid arthritis therapies

08-Jul-2010 - TcLand Expression SA announced the signature of a licensing agreement with Inserm Transfert. The terms of the agreement include the grant of worldwide, exclusive licenses to TcLand Expression for two different patents covering gene expression signatures which can predict responsiveness to ...

MorphoSys Receives Research Grant to Advance Anti-CD38 Cancer Program MOR202 and Explore Relevant Biomarkers

Project is Part of Munich's Cluster Initiative "m4 - Personalized Medicine and Targeted Therapies"

07-Jul-2010 - MorphoSys AG announced that it has been awarded a grant by the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 1 million supports MorphoSys in accelerating the development of its HuCAL-based cancer program MOR202 into clinical development for the ...

Ariadne to Collaborate in 7.5M€ Neuromuscular Disease Consortium to Find Biomarkers

05-Jul-2010 - Ariadne announces a new collaboration with the BIO-NMD consortium led by Professor Alessandra Ferlini at the University of Ferrara, Italy. BIO-NMD is a three year EU-funded research project concentrating on the search for non-invasive biomarkers in people with Duchenne and Becker muscular ...

Anti-anxiety Compound BNC210 Phase I Trial Successful: Establishes Four-fold Increase in Blood Drug Levels Following Food Intake

22-Jun-2010 - Bionomics Limited announced it has completed its second Phase I clinical trial of its anti-anxiety compound BNC210. The aim of this trial was to determine whether administration of BNC210 with food alters blood levels of the drug. Dr Deborah Rathjen Bionomics’ CEO & Managing Director explained ...

QIAGEN Expands Partnership with Genome Diagnostics for Development of Tests in Prevention and Personalized Healthcare

Extended HLA testing portfolio includes products to assess tolerance for Lumiracoxib and for the early detection of inflammatory diseases

21-Jun-2010 - QIAGEN announced that it has entered into an agreement with the Dutch molecular diagnostic component supplier Genome Diagnostics which covers the development and commercialization of 6 new tests until 2011. QIAGEN believes that this collaboration will further expand the Company’s testing ...

Revotar Biopharmaceuticals AG Starts Phase II Clinical Trial in COPD Patients with inhaled Bimosiamose

14-Jun-2010 - Revotar Biopharmaceuticals AG announced the start of a Phase II study to evaluate the safety and efficacy of inhaled Bimosiamose, a pan-selectin antagonist, for the treatment of patients with chronic obstructive pulmonary disease (COPD). The trial is designed as a double-blind, placebo ...

Protagen Deepens Cooperation With Bayer Schering Pharma

11-Jun-2010 - Protagen AG and Bayer Schering Pharma AG announced the closing of a cooperation contract for discovery of novel biomarkers in Endometriosis. Endometriosis is a debilitating gynecological medical condition occuring in roughly 5% -10% of women worldwide. The golden standard of diagnosis is ...

Epistem's Biomarker Division Gains GCLP Accreditation

08-Jun-2010 - Epistem plc has announced that their Biomarker Division has been awarded Good Clinical Laboratory Practice (GCLP) accreditation status. The Biomarker Division conducts gene expression analysis to support clinical drug development programs within pharmaceutical and biotechnology organisations, ...

BioVaria 2010 Meets Increasing Demand from Industry and Venture Capitalists for Life-Science IP

BioVaria Spin-off Award goes to iThera Medical GmbH

26-Apr-2010 - Thirteen European technology transfer organizations from Germany, Austria, France and Norway teamed up this year for BioVaria 2010, presenting over 50 licensable biopharmaceutical inventions and eight promising spin-offs to business developers and investors from the international ...